Specific Biologics Appoints Dr. Richard Glickman to Board of Directors
Specific Biologics Inc., a precision in vivo genome editing company, announced on December 16, 2025, the appointment of Dr. Richard Glickman to its Board of Directors.1
Dr. Glickman is a biotechnology executive with over 30 years of experience, having founded or co-founded companies like StressGen Biotechnologies, Aspreva Pharmaceuticals (acquired for US$915 million), and Aurinia Pharmaceuticals.1
He has served as Chair of boards including Aurinia Pharmaceuticals, ESSA Pharma, and enGene, and received awards like Ernst and Young Entrepreneur of the Year.1
Paul J. Hastings, Chair of the Board, highlighted Dr. Glickman's expertise in building biotech companies and advancing platform technologies.1
Dr. Glickman expressed excitement about Specific Biologics' Dualase® platform for treating diseases like ALS.1
Frédéric Lemaître Auger is stepping down from the Board after contributing to corporate strategy and financing.1
Specific Biologics develops Dualase® for precise in vivo genome editing, focusing on neurodegenerative diseases with strong preclinical data.1
Sources:
1. https://www.prnewswire.com/news-releases/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors-302643391.html